Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:African_trypanosomiasis
|
| gptkbp:accessibility |
increased accessibility
|
| gptkbp:activities |
inhibits DNA synthesis
|
| gptkbp:advocates_for |
advocacy for neglected diseases
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2018
gptkb:European_Medicines_Agency in the European Union |
| gptkbp:availability |
available in many countries
|
| gptkbp:clinical_trial |
multiple clinical trials
Phase II/ III used in late-stage disease |
| gptkbp:collaborations |
collaborations with research institutions
|
| gptkbp:community_involvement |
increased community awareness
|
| gptkbp:composed_of |
gptkb:chemical_compound
|
| gptkbp:contraindication |
hypersensitivity to fexinidazole
|
| gptkbp:developed_by |
DN Di
|
| gptkbp:dissolved |
soluble in water
|
| gptkbp:duration |
10 days
|
| gptkbp:education |
patient education initiatives
|
| gptkbp:excretion |
primarily renal
|
| gptkbp:formulation |
tablet form
|
| gptkbp:healthcare |
improves health outcomes
improves healthcare access part of public health initiatives |
| https://www.w3.org/2000/01/rdf-schema#label |
fexinidazole
|
| gptkbp:indication |
Human African Trypanosomiasis
|
| gptkbp:ingredients |
C19 H22 N4 O3 S
|
| gptkbp:interacts_with |
few drug interactions
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
monitoring of treatment response
|
| gptkbp:is_used_for |
treatment of sleeping sickness
|
| gptkbp:lifespan |
approximately 12 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
the brand name Fexinidazole
|
| gptkbp:packaging |
blister packs
|
| gptkbp:pharmacokinetics |
included
good oral bioavailability |
| gptkbp:population |
adults and children
|
| gptkbp:price |
affordable treatment option
|
| gptkbp:provides_information_on |
included in treatment guidelines
updated treatment guidelines |
| gptkbp:receives_funding_from |
funded by public and private sectors
|
| gptkbp:regulatory_compliance |
received regulatory approval
|
| gptkbp:research_focus |
neglected tropical diseases
Drugs for Neglected Diseases initiative |
| gptkbp:safety_features |
generally well tolerated
ongoing safety monitoring |
| gptkbp:scholarships |
support programs for patients
|
| gptkbp:side_effect |
dizziness
fatigue headache nausea rare serious adverse effects |
| gptkbp:storage |
store at room temperature
|
| gptkbp:targets |
gptkb:Trypanosoma_brucei_gambiense
|
| gptkbp:training |
training for healthcare providers
|
| gptkbp:treatment |
high efficacy
positive clinical outcomes |
| gptkbp:type_of |
1202560-51-5
|
| gptkbp:type_of_care |
high adherence rates
|
| gptkbp:weight |
378.46 g/mol
|
| gptkbp:year_created |
gptkb:2010
|